Shire’s New ADHD Drug Coming Into Focus
This article was originally published in The Pink Sheet Daily
Executive Summary
Connexyn (guanfacine extended release) could be approved in mid-2007 and would be the second non-stimulant in category.
You may also be interested in...
Shire Receives “Approvable” Letter For Intuniv To Treat ADHD
Shire expects to make a “timely” response to FDA’s concerns, which center on labeling, risk management issues, firm tells “The Pink Sheet” DAILY.
Shire Receives “Approvable” Letter For Intuniv To Treat ADHD
Shire expects to make a “timely” response to FDA’s concerns, which center on labeling, risk management issues, firm tells “The Pink Sheet” DAILY.
Shire Receives FDA “Approvable” Letter On Adult Adderall Product
With an adult filing for Adderall replacement Vyvanse set for mid year, the company is weighing its options, Shire told “The Pink Sheet” DAILY.